National Cancer Institute (NCI): all 3,554 studies

Page 28 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
• Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
• Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
• MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00101179Phase 1
• Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00101114Phase 2
• Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
• Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast CancerCompletedNCT00100750Phase 1/2
• Surgery for Pancreatic Tumors and Collection of Tumor Tissue for StudyTerminatedNCT00100321
• Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care UnitsCompletedNCT00099775Phase 3
• Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type IICompletedNCT00099112
• Lapatinib in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00099060Phase 1/2
• UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy ParticipantsCompletedNCT00098969Phase 1
• MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
• SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
• Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00098618Phase 2
• Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00098605Phase 2
• Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By SurgeryCompletedNCT00098579Phase 1
• Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00098540Phase 2
• FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction CancerTerminatedNCT00098527Phase 2
• CCI-779 and EKB-569 in Treating Patients With Advanced Solid TumorsCompletedNCT00098501Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098488Phase 1
• Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
• FR901228 in Treating Patients With Metastatic Breast CancerCompletedNCT00098397Phase 2
• Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing SurgeryCompletedNCT00096590
• A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive TherapyCompletedNCT00096551Phase 1
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or PaclitaxelCompletedNCT00096499Phase 2
• Sorafenib in Treating Patients With Metastatic Breast CancerCompletedNCT00096434Phase 2
• Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian CancerCompletedNCT00096395Phase 2
• Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
• Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00096070Phase 2
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00095966Phase 2
• 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast CancerTerminatedNCT00095888Phase 2
• XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerTerminatedNCT00095693Phase 2
• Lapatinib in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT00095667Phase 2
• BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid TumorsCompletedNCT00095459Phase 1
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 1
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
• Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerCompletedNCT00093626Phase 2
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• S0432 Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00093418Phase 2
• Exercise in Women at Risk for Breast CancerCompletedNCT00092950Phase 2
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
• Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerTerminatedNCT00091611Phase 1
• Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00091338Phase 1
• Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity CancerTerminatedNCT00091195Phase 2
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical CellsCompletedNCT00091130Phase 2
• Bortezomib in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00091117Phase 1
• Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedNCT00091078Phase 2
• Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With SurgeryCompletedNCT00091039Not applicable
• Cilengitide in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00089388Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00089349Phase 2
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney TransplantCompletedNCT00089180Phase 2
• Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00089154Phase 2
• Decitabine in Treating Patients With Advanced Refractory Solid Tumors or LymphomasTerminatedNCT00089089Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaCompletedNCT00089063Phase 2
• Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00088959Phase 1
• Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal CancerTerminatedNCT00088933Phase 1
• Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00088894Phase 3
• Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple MyelomaCompletedNCT00088855Phase 2
• Effect of Tenofovir DF on Bone Metabolism in ChildrenCompletedNCT00088309Phase 2
• S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerCompletedNCT00087412Phase 2
• Tanespimycin in Treating Patients With Stage III-IV MelanomaTerminatedNCT00087386Phase 2
• Vaccine Therapy in Treating Patients With Metastatic MelanomaTerminatedNCT00087373Phase 2
• Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionTerminatedNCT00087269Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid TumorCompletedNCT00087217Phase 1
• Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal TumorCompletedNCT00087074Phase 2
• Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid TumorsTerminatedNCT00086983Phase 1
• Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid TumorsTerminatedNCT00086970Phase 1
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• Romidepsin in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT00086827Phase 2
• Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube CancersCompletedNCT00086567
• Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT00085553Phase 1
• Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the PancreasCompletedNCT00085371Phase 2
• Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
• Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00085280Not applicable
• LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaCompletedNCT00085150Phase 1
• Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00085124Phase 3
• Bevacizumab in Treating Young Patients With Refractory Solid TumorsCompletedNCT00085111Phase 1
• Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung CancerCompletedNCT00084981Phase 1
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
• Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00084877Phase 1
• GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid TumorsCompletedNCT00084643Phase 1
• Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
• Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT00084604Phase 2
• Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
• Genetic and Protein Profiling in Normal and Cancerous Breast TissueCompletedNCT00083733
• Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) CancerCompletedNCT00083109Phase 1/2
• Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2

← National Cancer Institute (NCI) overview and focus areas